After a detailed examination, the DGTR concluded that the product under consideration is likely to be dumped in significant volumes in the event of expiry of duty
The company has reported a jump of 67% YoY with a total income of Rs. 58.55 crores
Company expects to commence manufacturing of Ethylamines by the end of this financial year
The capital expenditure during the half year ended 30th September, 2020 was Rs. 62 crore.
During the quarter ended Sep 2020, the company's consolidated total income stood at Rs. 4,620 crores as against Rs. 4,867 crores last year
Company's revenue from operations grew by 15% and stood at Rs 9,014 crore as against Rs 7,841 crore in the same period last year.
Company has already procured land for further expanding its existing Metformin capacity to 3,000 TPM in a brownfield expansion
The company already has an existing R&D center in Gurgaon for generation of scientific data and evaluation of new molecules.
The Fine & Specialty Chemicals (FSC) segment delivered a stellar performance with revenue growth of 52% y-o-y.
The Group increased sales to $5.4 billion, which is 5 percent higher compared to the same period last year while EBITDA increased by 1 percent to $733 million.
The company has achieved this significant growth due to large quantities of Dichloro Diphenyl Trichloroethane (DDT) and agrochemicals shipped to Southern African countries, Latin America and Iran during the period.
Revenue for Q2 FY21 stood at Rs. 509.34 million which grew by 19.4% as compared to Q2 FY20.
Company has registered a drop of 16% in Q3 operating profit to CHF 127 million ($140 million), with the profit margin narrowing to 14.2% from 14.5%.
Company has posted a growth of 16.47% YoY with a total income of Rs.328.57 crores
The jump in profit is due to the fact that PI Industries witnessed 25 per cdbt increase in exports and 33 per cent rise in domestic revenue.
Company reported consolidated income of Rs. 2,609 crore in Q2 FY21, up by 11% as compared to Rs. 2,348 crore last year.
Company's gross profit grew by 51.5% YoY to Rs.132 crore in Q2 FY21.
The company has made investments of about Rs. 105 crore in its 90 acre greenfield project, out of the total capex of Rs. 150 crore and is expecting to commence manufacturing of Ethylamines by the end of the last quarter of this financial year.
The new state-of-the-art preservation system for the Cosmenyl 100 range does not contain ortho-phenylphenol (O-PP), methylisothiazolinone (MIT) or parabens.
As per the agreement, Piramal Pharma will buy 49% stake of Navin Fluorine Rs. 65.10 crore thus becoming 100% owner of CCPL.
Subscribe to our newsletter & stay updated.
